{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:32:44Z","timestamp":1782480764999,"version":"3.54.5"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and\/or traction bronchiectasis plus reticulation, without atypical features of usual interstitial pneumonia (UIP), on high-resolution computed tomography (HRCT). Thus, the patients in these trials represented patients with definite UIP and a large subgroup of patients with possible UIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the potential impact of diagnostic subgroups on the progression of IPF and the effect of nintedanib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a post hoc subgroup analysis of patients with honeycombing on HRCT and\/or confirmation of UIP by biopsy versus patients without either, using pooled data from the INPULSIS trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Seven hundred twenty-three (68.1%) patients had honeycombing and\/or biopsy, and 338 (31.9%) patients had no honeycombing or biopsy. In these subgroups, respectively, the adjusted annual rate of decline in FVC in patients treated with placebo was \u2212225.7 and \u2212221.0 ml\/yr, and the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 117.0 ml\/yr (95% confidence interval, 76.3\u2013157.8) and 98.9 ml\/yr (95% confidence interval, 36.4\u2013161.5). There was no significant treatment-by-subgroup interaction (P\u2009=\u20090.8139). Adverse events were similar between the subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with IPF diagnosed in clinical practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lung biopsy had disease that progressed in a similar way, and responded similarly to nintedanib, to that of patients with honeycombing on HRCT and\/or confirmation of UIP by biopsy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201602-0402oc","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T17:28:45Z","timestamp":1466616525000},"page":"78-85","source":"Crossref","is-referenced-by-count":141,"title":["Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria"],"prefix":"10.1093","volume":"195","author":[{"given":"Ganesh","family":"Raghu","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol U.","family":"Wells","sequence":"additional","affiliation":[{"name":"Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Nicholson","sequence":"additional","affiliation":[{"name":"Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"University of Michigan Health System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Le Maulf","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim France S.A.S., Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozsa","family":"Schlenker-Herceg","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Hansell","sequence":"additional","affiliation":[{"name":"Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,1]]},"reference":[{"key":"2026032023302117500_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023302117500_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1164\/rccm.200606-833OC","article-title":"Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?","volume":"175","author":"Flaherty","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023302117500_bib3","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1164\/rccm.200402-147OC","article-title":"Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?","volume":"170","author":"Flaherty","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023302117500_bib4","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.athoracsur.2006.10.002","article-title":"Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease","volume":"83","author":"Kreider","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"2026032023302117500_bib5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1183\/09031936.00131912","article-title":"Prevalence and prognosis of unclassifiable interstitial lung disease","volume":"42","author":"Ryerson","year":"2013","journal-title":"Eur Respir J"},{"key":"2026032023302117500_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.resinv.2014.12.005","article-title":"Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?","volume":"53","author":"Huie","year":"2015","journal-title":"Respir Investig"},{"key":"2026032023302117500_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S2213-2600(15)00096-X","article-title":"CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society","volume":"3","author":"Hansell","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026032023302117500_bib8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"2026032023302117500_bib9","article-title":"OFEV (nintedanib) prescribing information. 2016 [accessed 2016 Apr 15]","author":"Boehringer Ingelheim Pharmaceuticals, Inc"},{"key":"2026032023302117500_bib10","article-title":"OFEV (nintedanib). Summary of product characteristics. 2016 [accessed 2016 Apr 18]","author":"Boehringer Ingelheim"},{"key":"2026032023302117500_bib11","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023302117500_bib12","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032023302117500_bib13","first-page":"A1022","article-title":"Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS trials in IPF [abstract]","volume":"191","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023302117500_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1164\/rccm.200412-1756OC","article-title":"High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis","volume":"172","author":"Lynch","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023302117500_bib15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.rmed.2015.02.008","article-title":"Clinical findings and outcomes in patients with possible usual interstitial pneumonia","volume":"109","author":"Lee","year":"2015","journal-title":"Respir Med"},{"key":"2026032023302117500_bib16","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1148\/rg.2015140334","article-title":"American Thoracic Society-European Respiratory Society classification of the idiopathic interstitial pneumonias: advances in knowledge since 2002","volume":"35","author":"Sverzellati","year":"2015","journal-title":"Radiographics"},{"key":"2026032023302117500_bib17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/resp.12531","article-title":"HRCT of fibrosing lung disease","volume":"20","author":"Jacob","year":"2015","journal-title":"Respirology"},{"key":"2026032023302117500_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/09031936.00217614","article-title":"Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry","volume":"46","author":"Behr","year":"2015","journal-title":"Eur Respir J"},{"key":"2026032023302117500_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","article-title":"Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants","volume":"69","author":"Walsh","year":"2014","journal-title":"Thorax"},{"key":"2026032023302117500_bib20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1148\/radiol.12112516","article-title":"Interobserver variability in the CT assessment of honeycombing in the lungs","volume":"266","author":"Watadani","year":"2013","journal-title":"Radiology"},{"key":"2026032023302117500_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/thoraxjnl-2015-207252","article-title":"Interobserver agreement for the ATS\/ERS\/JRS\/ALAT criteria for a UIP pattern on CT","volume":"71","author":"Walsh","year":"2016","journal-title":"Thorax"},{"key":"2026032023302117500_bib22","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/195\/1\/78\/67124787\/ajrccm_195_1_78.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/195\/1\/78\/67124787\/ajrccm_195_1_78.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:32:02Z","timestamp":1774063922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/195\/1\/78\/8498950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,1]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201602-0402oc","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726441406.793527364","asserted-by":"object"}]},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2017,1,1]]}}}